The investigators designed a stacked membrane assembly to manage sample movement and assay execution without external instrumentation. Short, direct statement: the device is a miniaturized multilayer vertical flow paper system. The paper-based stack incorporates 3D-printed glass fiber membranes, wax-printed nitrocellulose membranes, and cellulose absorption membranes. Together these materials perform two linked tasks: autonomous wicking of the input sample through the stack and concurrent splitting of that sample into multiple equal streams. By combining a porous glass fiber layer with patterned nitrocellulose and an absorbent cellulose sink, the authors achieved internal flow control that carries out both the sandwich immunoassay and wash steps in sequence, all driven by capillary action.
The team reported a compact physical footprint (about 12.5 cm3). This small form factor supports portability for point-of-care or field use. The source abstract did not provide details of layer thicknesses, pore sizes, or specific 3D printing parameters; those manufacturing and microfluidic design parameters were not reported in the excerpt and therefore are not restated here.
Data indicated the platform performs simultaneous quantification of 12 protein biomarkers in a single run. That level of multiplexing was accomplished by distributing the microliter sample into multiple assay zones while preserving assay integrity and avoiding reported cross-interference within the abstract. The authors described the assay format as sandwich immunoassays executed in parallel across the device.
Operationally, the device required about 60 μL of blood to complete the multiplexed assay. Results were delivered in roughly 15 minutes. Those two metrics—sample volume and time-to-result—are central to the platform’s clinical utility in rapid screening contexts such as emergency triage or at-home monitoring. The abstract did not include numerical analytical performance metrics such as limits of detection, dynamic range, intra- or inter-assay precision, or cross-reactivity panels; the source text did not report those specific assay performance values.
The authors validated clinical performance using samples from patients diagnosed with acute myocardial infarction (AMI), acute kidney disease (AKD), and sepsis. The abstract states that clinical samples were used to evaluate the platform, implying translation beyond purely benchtop demonstrations. The report links the biomarker panel to screening for heart disease, kidney disease, and inflammation, although the abstract did not list the individual biomarkers by name or report sensitivity and specificity outcomes for each diagnostic category.
Investigators framed potential applications in scenarios where rapid disease screening is needed, including home healthcare and emergency care. The use of real patient samples for validation supports the claim that the device can operate with clinical matrices; the source, however, did not disclose the sample collection protocol, patient numbers, or statistical validation results in the abstract.
Practically speaking, the device needs about 60 μL of sample—an amount obtainable from a fingerstick in most settings. Turnaround time is approximately 15 minutes from sample introduction to readout. The compact device volume (reported as 12.5 cm3) and the absence of active pumps or external reagents during the run suggest straightforward user operation and rapid deployment.
The architecture performs both reagent delivery and wash functions intrinsically via the layered membranes and capillary-driven flow. That strategy reduces user steps and the need for external fluid handling. The abstract did not specify how end-users read results (visual readout, colorimetric intensity, or digital detection), nor did it describe storage stability, shelf life, or environmental operating conditions—those operational specifics were not provided in the source excerpt.
The abstract identified core challenges that the device aims to address—multiplex detection without cross-interference, system miniaturization, reliable flow manipulation, and simple operation—and presented the multilayer membrane design as the engineering response. Concrete limitations and unanswered questions remain in the published abstract. The authors did not report key analytical metrics such as limits of detection, quantitative accuracy, or cross-reactivity tables within the provided text. They also did not detail the identities of the 12 biomarkers, nor did they provide numerical clinical performance measures (for example, sensitivity, specificity, or receiver-operating-characteristic parameters) in the abstract.
Funding and institutional support are listed in the publication metadata and include Peking University and national Chinese research grants. The abstract does not state regulatory status, commercial availability, or planned next steps. Readers seeking those specifics will need to consult the full article for manufacturing parameters, complete biomarker lists, assay validation data, and any user-interface or readout methods that the team used in clinical validation.